AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

Colon cancer has been on the rise in Americans under 50 for the last three decades, but it’s not exactly clear why.

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and ...

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

Long-term yogurt consumption is associated with a reduced risk of Bifidobacterium-positive colorectal cancer, particularly in ...

Don’t hesitate to talk to your doctor about colorectal cancer, even if it may feel uncomfortable. Ask about screenings if you ...

Q4 2024 Management View CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, ...

体检报告上，最让人摸不着头脑的几个词之一，可能就是“息肉”。 胃息肉、肠息肉、胆囊息肉……光是看到名字，就让人心里犯嘀咕：“这玩意儿严重吗？”“需要切掉吗？”“会不会变成癌？” ...

大多数息肉都是良性的，不需要立即处理。不过由于息肉是向外生长的，因此有可能堵塞管腔造成症状，并且部分息肉存在变为恶性的可能，因此我们需要辨别哪些息肉可以继续观察，哪些息肉需要及时处理。

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial ...

Aspirin is not only one of the best-documented medicines in the world, but also one of the most frequently used drugs of all times. In addition to its role as an analgesic, aspirin is being ...